<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084278</url>
  </required_header>
  <id_info>
    <org_study_id>MPC-004-09-1028</org_study_id>
    <secondary_id>U1111-1132-3386</secondary_id>
    <nct_id>NCT01084278</nct_id>
  </id_info>
  <brief_title>Healthy and Renal Impairment Study of Colcrys (Colchicine, USP)</brief_title>
  <official_title>Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the pharmacokinetic profiles of colchicine
      and its primary metabolites in plasma and urine following a single 0.6 mg oral dose of
      colchicine in healthy adults with normal renal function, in patients with mild, moderate or
      severe renal impairment, and in patients with end-stage renal disease on hemodialysis. An
      additional objective of this study is to study the clearance of colchicine and its
      metabolites by hemodialysis. Secondary objectives include evaluation of the safety and
      tolerability of colchicine in the study population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      40 male and female subjects will be enrolled in the study and stratified into one of five
      groups based on their renal status as determined from creatinine clearance (CrCL) estimated
      using the serum creatinine (sCR) and the Cockcroft-Gault and Modified Diet in Renal Disease
      (MDRD) equations as follows: Treatment group 1 - healthy adults with normal renal function
      (CrCL/eGFR&gt; 90 mL/min); Treatment groups 2, 3 and 4 - patients with mild (CrCL/eGFR 60-89
      mL/min), moderate (CrCL/eGFR 30 to 59 mL/min), and severe (CrCL/eGFR 15 to 29 mL/min) renal
      impairment, respectively; and Treatment group 5 - subjects with end-stage renal disease
      requiring hemodialysis. On study day 1, participants in Treatment Groups 1 to 4 will be
      administered one colchicine 0.6 mg tablet at 8 a.m. under standard fasting conditions. Blood
      samples will be collected from all participants before dosing and both blood and urine
      samples will be collected for 120 hours post-dose on a confined basis at times sufficient to
      adequately define the pharmacokinetics of colchicine and its primary metabolites. There will
      be two study periods for treatment group 5; Period 1 off dialysis and Period 2 on dialysis
      with a 14 day washout period between the two study periods. On study day 1, participants in
      treatment group 5 will be administered one colchicine 0.6 mg tablet under standard fasting
      conditions immediately following dialysis. Blood samples will be collected from all
      participants before dosing and for up to 70 hours post-dose at times sufficient to adequately
      determine the pharmacokinetics of colchicine and its primary metabolites. All adverse events
      will be evaluated by the investigator and reported in the participant's case report form.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose</time_frame>
    <description>The maximum or peak concentration of colchicine in the plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Day 1 and Day 15 (for ESRD patients only) at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose</time_frame>
    <description>The time to reach the maximum or peak concentration of colchicine in the plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Time Curve From Time Zero to the Time of Last Measured Concentration (AUC 0-t)</measure>
    <time_frame>Day 1 and Day 15 (ESRD patients only), predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose</time_frame>
    <description>The area under the plasma concentration versus time curve beginning from the first dose until the last quantifiable concentration, calculated by the linear trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Time Curve From Time Zero to Infinity (AUC 0 - ∞)</measure>
    <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
    <description>The area under the plasma concentration versus time curve extrapolated to infinity. AUC 0 - ∞ is calculated as the sum of total AUC 0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent First-order Terminal Elimination Rate Constant (Kel)</measure>
    <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
    <description>Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma concentration versus time curve for colchicine. The parameter was calculated by linear least-squares regression analysis using the maximum number of points in the terminal log-linear phase (e.g., three or more non-zero plasma concentrations).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent First-order Terminal Elimination Half-life (t½)</measure>
    <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
    <description>The apparent first-order terminal elimination half-life was calculated as 0.693/Kel.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Apparent Total Volume of Distribution After Administration (V-area/F)</measure>
    <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
    <description>The apparent total volume of distribution after administration of colchicine, calculated as Dose / (AUC0-∞ × Kel).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight-adjusted Apparent Total Volume of Distribution After Administration (V-area/F)</measure>
    <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
    <description>The apparent total volume of distribution after administration of colchicine, calculated as Dose / (AUC0-∞ × Kel), and normalized to body weight.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance of Colchicine</measure>
    <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
    <description>The apparent total body clearance after administration of colchicine, calculated as Dose/AUC(0-∞).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight-adjusted Apparent Total Body Clearance of Colchicine</measure>
    <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
    <description>The apparent total body clearance after administration of colchicine, calculated as Dose/AUC(0-∞) and normalized to body weight (in kilograms).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Colchicine Excreted in Urine (Ae[0-t])</measure>
    <time_frame>Pre-dose on Day 1 and up to 120 hours post dose.</time_frame>
    <description>The amount of colchicine excreted in urine during the post-dose collection, calculated as the sum of the amounts in the individual collection intervals (Ae).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Colchicine Dose Excreted in Urine up to the Final Collection Time</measure>
    <time_frame>Pre-dose on Day 1 and up to 120 hours post dose.</time_frame>
    <description>The cumulative percentage of the colchicine dose excreted in urine up to the final collection time, calculated as Ae(0-t) × 100/dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance of Colchicine (CLR)</measure>
    <time_frame>Pre-dose on Day 1 and up to 120 hours post dose.</time_frame>
    <description>Renal clearance of colchicine, calculated as Ae(0 t)/AUC 0-t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dialysis Clearance of Colchicine (CLD)</measure>
    <time_frame>Day 15, post-dose during dialysis</time_frame>
    <description>The dialysis clearance of colchicine, calculated as amount of colchicine recovered in dialysate / AUCt2-t1 where t1 and t2 are the times of the start and end of hemodialysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Colchicine Dose Recovered in Dialysate</measure>
    <time_frame>Day 15, post-dose during dialysis</time_frame>
    <description>The cumulative percentage of the colchicine dose recovered in dialysate.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate renal impairment (CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>End stage renal disease (ESRD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine tablets</description>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Mild renal impairment</arm_group_label>
    <arm_group_label>Moderate renal impairment</arm_group_label>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_label>End stage renal disease (ESRD)</arm_group_label>
    <other_name>COLCRYS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult males and females 18-70 years old with a body mass index of &lt;39 kg/m^2.

          -  Patients with normal renal function or mild renal impairment should be generally
             healthy on the basis of medical history and physical exam.

          -  Patients with moderate to end stage renal impairment should be generally medically
             healthy other than with respect to the morbidities associated with impaired renal
             function.

          -  Non-pregnant (post-menopausal, surgically sterile or using effective contraceptive
             measures).

        Exclusion Criteria:

          -  Known hypersensitivity to colchicine or any component of the formulation of the study
             drug.

          -  Patients with a history or presence of a significant medical condition that would
             interfere with interpretation of the study results.

          -  Patients who have used any drugs or substances known to inhibit or induce cytochrome
             P450 (CYP) enzymes and/or P-glycoprotein within 28 days prior to the first dose and
             throughout the study.

          -  Patients with recent (2 year) history or evidence of alcoholism or drug abuse or
             significant psychiatric disease.

          -  Patients with chronic hepatic dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Davis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mutual Pharmaceutical Company, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier T Quesada, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Coast Clinical Trials, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>September 11, 2012</results_first_submitted>
  <results_first_submitted_qc>September 11, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 12, 2012</results_first_posted>
  <disposition_first_submitted>March 12, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>March 16, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 20, 2012</disposition_first_posted>
  <last_update_submitted>September 11, 2012</last_update_submitted>
  <last_update_submitted_qc>September 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at three investigative sites in the United States from 25 May 2010 to 28 February 2011.</recruitment_details>
      <pre_assignment_details>Healthy participants, participants with mild, moderate or severe renal impairment and participants with end stage renal disease (requiring hemodialysis) were stratified to one of five treatment groups based on their renal status. All participants received 0.6 mg colchicine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy</title>
          <description>Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="P2">
          <title>Mild</title>
          <description>Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="P3">
          <title>Moderate</title>
          <description>Participants with moderate renal impairment CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="P4">
          <title>Severe</title>
          <description>Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="P5">
          <title>ESRD</title>
          <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy</title>
          <description>Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="B2">
          <title>Mild</title>
          <description>Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="B3">
          <title>Moderate</title>
          <description>Participants with moderate renal impairment CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="B4">
          <title>Severe</title>
          <description>Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="B5">
          <title>ESRD</title>
          <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="5.29"/>
                    <measurement group_id="B2" value="63.9" spread="3.94"/>
                    <measurement group_id="B3" value="63.0" spread="5.4"/>
                    <measurement group_id="B4" value="57.6" spread="8.48"/>
                    <measurement group_id="B5" value="42.2" spread="12.85"/>
                    <measurement group_id="B6" value="55.85" spread="10.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other pacific islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child Bearing Potential</title>
          <description>Counts are based on the number of female participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine Clearance/estimated Glomerular Filtration Rate</title>
          <description>Creatinine Clearance for Healthy Treatment Group and estimated Glomerular Filtration Rate for Mild, Moderate, Severe and ESRD Treatment Groups.</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111.49" spread="22.651"/>
                    <measurement group_id="B2" value="73.3" spread="8.10"/>
                    <measurement group_id="B3" value="40.0" spread="6.78"/>
                    <measurement group_id="B4" value="22" spread="4.17"/>
                    <measurement group_id="B5" value="10.9" spread="2.97"/>
                    <measurement group_id="B6" value="55.70" spread="36.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.33" spread="7.722"/>
                    <measurement group_id="B2" value="167.94" spread="8.865"/>
                    <measurement group_id="B3" value="164.83" spread="9.054"/>
                    <measurement group_id="B4" value="172.06" spread="8.643"/>
                    <measurement group_id="B5" value="168.05" spread="11.991"/>
                    <measurement group_id="B6" value="169.09" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.09" spread="8.494"/>
                    <measurement group_id="B2" value="65.55" spread="9.904"/>
                    <measurement group_id="B3" value="77.55" spread="10.667"/>
                    <measurement group_id="B4" value="100.81" spread="16.856"/>
                    <measurement group_id="B5" value="73.86" spread="22.287"/>
                    <measurement group_id="B6" value="78.95" spread="18.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.54" spread="2.113"/>
                    <measurement group_id="B2" value="23.18" spread="2.560"/>
                    <measurement group_id="B3" value="28.64" spread="4.823"/>
                    <measurement group_id="B4" value="33.96" spread="4.489"/>
                    <measurement group_id="B5" value="25.66" spread="5.018"/>
                    <measurement group_id="B6" value="27.60" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <description>The maximum or peak concentration of colchicine in the plasma.</description>
        <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <description>The maximum or peak concentration of colchicine in the plasma.</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="0.68"/>
                    <measurement group_id="O2" value="2.73" spread="0.78"/>
                    <measurement group_id="O3" value="3.69" spread="1.42"/>
                    <measurement group_id="O4" value="2.53" spread="0.73"/>
                    <measurement group_id="O5" value="2.67" spread="0.94"/>
                    <measurement group_id="O6" value="2.27" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax)</title>
        <description>The time to reach the maximum or peak concentration of colchicine in the plasma.</description>
        <time_frame>Day 1 and Day 15 (for ESRD patients only) at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax)</title>
          <description>The time to reach the maximum or peak concentration of colchicine in the plasma.</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.37"/>
                    <measurement group_id="O2" value="1.01" spread="0.04"/>
                    <measurement group_id="O3" value="1.31" spread="0.37"/>
                    <measurement group_id="O4" value="1.58" spread="0.68"/>
                    <measurement group_id="O5" value="1.31" spread="0.46"/>
                    <measurement group_id="O6" value="1.29" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Time Curve From Time Zero to the Time of Last Measured Concentration (AUC 0-t)</title>
        <description>The area under the plasma concentration versus time curve beginning from the first dose until the last quantifiable concentration, calculated by the linear trapezoidal method.</description>
        <time_frame>Day 1 and Day 15 (ESRD patients only), predose and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve From Time Zero to the Time of Last Measured Concentration (AUC 0-t)</title>
          <description>The area under the plasma concentration versus time curve beginning from the first dose until the last quantifiable concentration, calculated by the linear trapezoidal method.</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.37" spread="7.75"/>
                    <measurement group_id="O2" value="25.83" spread="5.43"/>
                    <measurement group_id="O3" value="43.94" spread="11.68"/>
                    <measurement group_id="O4" value="40.44" spread="13.58"/>
                    <measurement group_id="O5" value="26.09" spread="8.73"/>
                    <measurement group_id="O6" value="22.65" spread="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Time Curve From Time Zero to Infinity (AUC 0 - ∞)</title>
        <description>The area under the plasma concentration versus time curve extrapolated to infinity. AUC 0 - ∞ is calculated as the sum of total AUC 0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
        <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Time Curve From Time Zero to Infinity (AUC 0 - ∞)</title>
          <description>The area under the plasma concentration versus time curve extrapolated to infinity. AUC 0 - ∞ is calculated as the sum of total AUC 0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.73" spread="8.10"/>
                    <measurement group_id="O2" value="27.21" spread="5.56"/>
                    <measurement group_id="O3" value="48.94" spread="13.45"/>
                    <measurement group_id="O4" value="48.00" spread="17.36"/>
                    <measurement group_id="O5" value="31.68" spread="12.28"/>
                    <measurement group_id="O6" value="30.61" spread="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent First-order Terminal Elimination Rate Constant (Kel)</title>
        <description>Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma concentration versus time curve for colchicine. The parameter was calculated by linear least-squares regression analysis using the maximum number of points in the terminal log-linear phase (e.g., three or more non-zero plasma concentrations).</description>
        <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent First-order Terminal Elimination Rate Constant (Kel)</title>
          <description>Apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma concentration versus time curve for colchicine. The parameter was calculated by linear least-squares regression analysis using the maximum number of points in the terminal log-linear phase (e.g., three or more non-zero plasma concentrations).</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>1/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.023" spread="0.004"/>
                    <measurement group_id="O2" value="0.023" spread="0.003"/>
                    <measurement group_id="O3" value="0.018" spread="0.002"/>
                    <measurement group_id="O4" value="0.014" spread="0.002"/>
                    <measurement group_id="O5" value="0.025" spread="0.006"/>
                    <measurement group_id="O6" value="0.020" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent First-order Terminal Elimination Half-life (t½)</title>
        <description>The apparent first-order terminal elimination half-life was calculated as 0.693/Kel.</description>
        <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent First-order Terminal Elimination Half-life (t½)</title>
          <description>The apparent first-order terminal elimination half-life was calculated as 0.693/Kel.</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.63" spread="5.43"/>
                    <measurement group_id="O2" value="30.92" spread="3.54"/>
                    <measurement group_id="O3" value="39.90" spread="3.93"/>
                    <measurement group_id="O4" value="49.53" spread="6.01"/>
                    <measurement group_id="O5" value="29.38" spread="7.51"/>
                    <measurement group_id="O6" value="40.80" spread="21.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Apparent Total Volume of Distribution After Administration (V-area/F)</title>
        <description>The apparent total volume of distribution after administration of colchicine, calculated as Dose / (AUC0-∞ × Kel).</description>
        <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>The Apparent Total Volume of Distribution After Administration (V-area/F)</title>
          <description>The apparent total volume of distribution after administration of colchicine, calculated as Dose / (AUC0-∞ × Kel).</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1131.68" spread="247.32"/>
                    <measurement group_id="O2" value="1024.22" spread="266.47"/>
                    <measurement group_id="O3" value="761.81" spread="237.07"/>
                    <measurement group_id="O4" value="1009.02" spread="419.88"/>
                    <measurement group_id="O5" value="870.46" spread="230.68"/>
                    <measurement group_id="O6" value="1263.0" spread="462.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weight-adjusted Apparent Total Volume of Distribution After Administration (V-area/F)</title>
        <description>The apparent total volume of distribution after administration of colchicine, calculated as Dose / (AUC0-∞ × Kel), and normalized to body weight.</description>
        <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight-adjusted Apparent Total Volume of Distribution After Administration (V-area/F)</title>
          <description>The apparent total volume of distribution after administration of colchicine, calculated as Dose / (AUC0-∞ × Kel), and normalized to body weight.</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>L/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.84" spread="3.36"/>
                    <measurement group_id="O2" value="15.80" spread="3.94"/>
                    <measurement group_id="O3" value="10.06" spread="3.65"/>
                    <measurement group_id="O4" value="9.91" spread="3.10"/>
                    <measurement group_id="O5" value="13.35" spread="6.94"/>
                    <measurement group_id="O6" value="18.91" spread="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance of Colchicine</title>
        <description>The apparent total body clearance after administration of colchicine, calculated as Dose/AUC(0-∞).</description>
        <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance of Colchicine</title>
          <description>The apparent total body clearance after administration of colchicine, calculated as Dose/AUC(0-∞).</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.34" spread="7.57"/>
                    <measurement group_id="O2" value="23.04" spread="5.60"/>
                    <measurement group_id="O3" value="13.63" spread="5.80"/>
                    <measurement group_id="O4" value="14.59" spread="7.37"/>
                    <measurement group_id="O5" value="22.07" spread="9.87"/>
                    <measurement group_id="O6" value="25.78" spread="15.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Weight-adjusted Apparent Total Body Clearance of Colchicine</title>
        <description>The apparent total body clearance after administration of colchicine, calculated as Dose/AUC(0-∞) and normalized to body weight (in kilograms).</description>
        <time_frame>Day 1 and Day 15 (for ESRD patients only) pre-dose and at 0.5, 1, 1.5 , 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O5">
            <title>ESRD - Off Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken on study day 1 immediately following dialysis.</description>
          </group>
          <group group_id="O6">
            <title>ESRD - on Dialysis</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight-adjusted Apparent Total Body Clearance of Colchicine</title>
          <description>The apparent total body clearance after administration of colchicine, calculated as Dose/AUC(0-∞) and normalized to body weight (in kilograms).</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>L/hr/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.08"/>
                    <measurement group_id="O2" value="0.36" spread="0.12"/>
                    <measurement group_id="O3" value="0.18" spread="0.09"/>
                    <measurement group_id="O4" value="0.14" spread="0.06"/>
                    <measurement group_id="O5" value="0.35" spread="0.26"/>
                    <measurement group_id="O6" value="0.41" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of Colchicine Excreted in Urine (Ae[0-t])</title>
        <description>The amount of colchicine excreted in urine during the post-dose collection, calculated as the sum of the amounts in the individual collection intervals (Ae).</description>
        <time_frame>Pre-dose on Day 1 and up to 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Colchicine Excreted in Urine (Ae[0-t])</title>
          <description>The amount of colchicine excreted in urine during the post-dose collection, calculated as the sum of the amounts in the individual collection intervals (Ae).</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.110" spread="0.032"/>
                    <measurement group_id="O2" value="0.100" spread="0.026"/>
                    <measurement group_id="O3" value="0.094" spread="0.053"/>
                    <measurement group_id="O4" value="0.058" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Colchicine Dose Excreted in Urine up to the Final Collection Time</title>
        <description>The cumulative percentage of the colchicine dose excreted in urine up to the final collection time, calculated as Ae(0-t) × 100/dose</description>
        <time_frame>Pre-dose on Day 1 and up to 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Colchicine Dose Excreted in Urine up to the Final Collection Time</title>
          <description>The cumulative percentage of the colchicine dose excreted in urine up to the final collection time, calculated as Ae(0-t) × 100/dose</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>percent of dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.34" spread="5.39"/>
                    <measurement group_id="O2" value="16.69" spread="4.3"/>
                    <measurement group_id="O3" value="15.67" spread="8.77"/>
                    <measurement group_id="O4" value="9.63" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance of Colchicine (CLR)</title>
        <description>Renal clearance of colchicine, calculated as Ae(0 t)/AUC 0-t.</description>
        <time_frame>Pre-dose on Day 1 and up to 120 hours post dose.</time_frame>
        <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy</title>
            <description>Healthy participants with normal renal function received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild</title>
            <description>Participants with mild renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O3">
            <title>Moderate</title>
            <description>Participants with moderate renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
          <group group_id="O4">
            <title>Severe</title>
            <description>Participants with severe renal impairment received one colchicine 0.6 mg tablet on study day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance of Colchicine (CLR)</title>
          <description>Renal clearance of colchicine, calculated as Ae(0 t)/AUC 0-t.</description>
          <population>Per Protocol Analysis Population - Participants renal function was characterized by CrCl using the Cockcroft-Gault equation as healthy (≥90 mL/min), and characterized by Modified Diet in Renal Disease (MDRD) equations as mild (60 - 89 mL/min), moderate (30 - 59 mL/min), severe (15 - 29 mL/min), and ESRD patients requiring dialysis.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="0.51"/>
                    <measurement group_id="O2" value="3.90" spread="0.74"/>
                    <measurement group_id="O3" value="2.12" spread="0.86"/>
                    <measurement group_id="O4" value="1.69" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dialysis Clearance of Colchicine (CLD)</title>
        <description>The dialysis clearance of colchicine, calculated as amount of colchicine recovered in dialysate / AUCt2-t1 where t1 and t2 are the times of the start and end of hemodialysis.</description>
        <time_frame>Day 15, post-dose during dialysis</time_frame>
        <population>ESRD participants on dialysis, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>End Stage Renal Disease (ESRD)</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken under standard fasting conditions on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Dialysis Clearance of Colchicine (CLD)</title>
          <description>The dialysis clearance of colchicine, calculated as amount of colchicine recovered in dialysate / AUCt2-t1 where t1 and t2 are the times of the start and end of hemodialysis.</description>
          <population>ESRD participants on dialysis, where data were available.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Colchicine Dose Recovered in Dialysate</title>
        <description>The cumulative percentage of the colchicine dose recovered in dialysate.</description>
        <time_frame>Day 15, post-dose during dialysis</time_frame>
        <population>ESRD participants on dialysis, where data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>End Stage Renal Disease (ESRD)</title>
            <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet taken under standard fasting conditions on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Colchicine Dose Recovered in Dialysate</title>
          <description>The cumulative percentage of the colchicine dose recovered in dialysate.</description>
          <population>ESRD participants on dialysis, where data were available.</population>
          <units>percent dose</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug up to 6 days.</time_frame>
      <desc>The investigator documented any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy</title>
          <description>Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="E2">
          <title>Mild</title>
          <description>Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="E3">
          <title>Moderate</title>
          <description>Participants with moderate renal impairment CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="E4">
          <title>Severe</title>
          <description>Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.</description>
        </group>
        <group group_id="E5">
          <title>ESRD</title>
          <description>Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Infusion site induration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication related to study results will be made without Sponsor’s prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. VP, Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

